Page 1455 - Williams Hematology ( PDFDrive )

1430 Part X: Malignant Myeloid Diseases Chapter 88: Acute Myelogenous Leukemia 1431

908. Blum W, Klisovic RB, Becker H, et al: Dose escalation of lenalidomide in relapsed or 937. Hernandez JM, Martin G, Gutierrez MC, et al: Additional cytogenetic changes do not
refractory acute leukemias. J Clin Oncol 28:4919, 2010. influence the outcome of patients with newly diagnosed acute promyelocytic leuke-
909. Mardiors A, Dos Santos C, McDonald T, et al: T cells expressing CD123=specific mia treated with an ATRA plus anthracycline based protocol. A report of the Spanish
chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor group PETHEMA. Haematologica 86:807, 2001.
effects against human acute myeloid leukemia. Blood 122:3138, 2013. 938. Kennedy GA, Marlton P, Cobcroft R, Gill D: Molecular remission without blood prod-
910. Tettamanti S, Biondi A, Biagl E, et al: CD123 AML targeting by chimeric antigen uct support using all-trans retinoic acid (ATRA) induction and combined arsenic tri-
receptors. Oncoimmunology 3:e28835, 2014. oxide/ATRA consolidation in a Jehovah’s Witness with de novo acute promyelocytic
911. Rego EM, Kim HT, Ruiz-Arguelles GJ, et al: Improving acute promyelocytic leukemia leukemia. Br J Haematol 111:1103, 2000.
(APL) outcome in developing countries through networking, results of the Interna- 939. Martinelli G, Ottaviani E, Testoni N, et al: Disappearance of PML/RAR alpha acute
tional consortium on APL. Blood 121:1935, 2013. promyelocytic leukemia associated transcript during consolidation chemotherapy.
912. Sanz MA, Martin G, Gonzalez M, et al: Risk-adapted treatment of acute promyelo- Haematologica 83:985, 1998.
cytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: A 940. Fadilah SA, Hatta AZ, Keng CS, et al: Successful treatment of acute promyelocytic
multicenter study by the PETHEMA. Blood 103:1237, 2004. leukemia in pregnancy with all-trans retinoic acid. Leukemia 15:1665, 2001.
913. Avvisati G, Petti MC, Lo-Coco F, et al: Induction therapy with idarubicin alone sig- 941. Carridice D, Austin N, Bayston K, Ganly PS: Successful treatment of acute promyelo-
nificantly influences event-free survival duration in patients with newly diagnosed cytic leukaemia during pregnancy. Clin Lab Haematol 24:307, 2002.
hypergranular acute promyelocytic leukemia: Final results of the GIMEMA random- 942. Tallman MS, Andersen JW, Schiffer CA, et al: Clinical description of 44 patients with
ized study LAP 0389 with 7 years of minimal follow-up. Blood 100:3141, 2002. acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood
914. Sanz MA, Tallman MS, Lo-Coco F, et al: Practice points, consensus, and controversial 95:90, 2000.
issues in the management of patients with newly diagnosed acute promyelocytic leu- 943. Sanz MA, Montesinos P: How we prevent and treat differentiation syndrome in
kemia. Oncologist 10:806, 2005. patients with acute promyelocytic leukemia. Blood 123:2777, 2014.
915. Sanz MA, Lo-Coco F: Standard practice and controversial issues in front-line therapy 944. Larsen RS, Tallman MS: Retinoic acid syndrome: Manifestations, pathogenesis, and
of acute promyelocytic leukemia. Haematologica 90:840, 2005. treatment. Best Pract Res Clin Haematol 16:453, 2003.
916. Sanz MA, Grimwade D, Tallman MS, et al: Management of acute promyelocytic leu- 945. Frankel SR, Eardley A, Lauwers G, et al: The “retinoic acid syndrome” in acute promy-
kemia: Recommendations from an expert panel on behalf of the European Leukemi- elocytic leukemia. Ann Intern Med 117:292, 1992.
aNet. Blood 113:1875, 2009. 946. De Botton S, Dombret H, Sanz M, et al: Incidence, clinical features, and outcome of
917. Lengfelder E, Reichert A, Schoch C, et al: Double induction strategy including high all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic
dose cytarabine in combination with all-trans retinoic acid: Effects in patients with leukemia. The European APL Group. Blood 92:2712, 1998.
newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. 947. Azlin ZA, Ahmed T: Cure in acute promyelocytic leukemia—Now more readily
Leukemia 14:1362, 2000. achievable with less toxic therapy. Blood 79:2492, 1992.
918. Adès L, Sanz MA, Chevret S, et al: Treatment of newly diagnosed acute promyelo- 948. Tallman MS: Retinoic acid syndrome: A problem of the past? Leukemia 16:160, 2002.
cytic leukemia (APL): A comparison of French-Belgian-Swiss and PETHEMA results. 949. Falanga A, Barbui T: Coagulopathy of acute promyelocytic leukemia. Acta Haematol
Blood 111:1078, 2008. 106:43, 2001.
919. Sanz MA, Montesions P, Rayon C, et al: Risk-adapted treatment of acute promye- 950. Yanada M, Matsushita T, Asou N, et al: Severe hemorrhagic complications during
locytic leukemia based on all-trans retinoic acid and anthracycline with addition of remission induction therapy for acute promyelocytic leukemia: Incidence, risk fac-
cytarabine in consolidation therapy for high-risk patients; further improvements in tors, and influence on outcome. Eur J Haematol 78:213, 2007.
treatment outcome. Blood 115:5137, 2010. 951. Goldberg MA, Ginsburg D, Mayer RJ, et al: Is heparin administration necessary dur-
920. Iland HJ, Bradstock K, Supple SG, et al: All-trans-retinoic acid, idarubicin and IV ing induction chemotherapy for patients with acute promyelocytic leukemia? Blood
arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 69:187, 1987.
120:1570, 2012. 952. Visani G, Gugliotta L, Tosi P, et al: All-trans retinoic acid significantly reduces the
921. Lo-Coco F, Avvisati G, Vignetti M, et al: Retinoic acid and arsenic trioxide for acute incidence of early hemorrhagic death during induction therapy of acute promyelo-
promyelocytic leukemia. N Engl J Med 369:111, 2013. cytic leukemia. Eur J Haematol 64:139, 2000.
922. Lallemand-Breittenbach V, de The H: Retinoic acid plus arsenic trioxide, the ultimate 953. Jacomo RH, Santana-Lemos BA, Lima ASG, et al: Methionine-induced hyperhomo-
panacea for acute promyelocytic leukemia? Blood 122:2008, 2013. cysteinemia reverses fibrinolytic pathway activation in a murine model of actue pro-
923. Mandelli F, Latagliata R, Avvisati G, et al: Treatment of elderly patients (> or = 60 myelocytic leukemia. Blood 120:207, 2012.
years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian 954. Petti MC, Avvisati G, Amadori S, et al: Acute promyelocytic leukaemia: Clinical
multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. Leukemia aspects and results of treatment in 62 patients. Haematologica 72:151, 1987.
17:1085, 2003. 955. Kizaki M, Ueno H, Yamazoe Y, et al: Mechanisms of retinoid resistance in leukemic
924. Estey EH, Giles FJ, Beran M, et al: Experience with gemtuzumab ozogamicin (“Mylot- cells: Possible role of cytochrome P450 and P-glycoprotein. Blood 87:725, 1996.
arg”) and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 956. Adès L, Chevret S, Raffoux E, et al: Is cytarabine useful in the treatment of acute pro-
99:4222, 2002. myelocytic leukemia? Results of a randomized trial from the European Acute Promy-
925. Shen ZX, Shi ZZ, Fang J, et al: All-trans retinoic acid/As O combination yields a high elocytic Leukemia Group. J Clin Oncol 24:5703, 2006.
3
2
quality remission and survival in newly diagnosed acute promyelocytic leukemia. 957. Asou N, Kishimoto Y, Kiyoi H, et al: A randomized study with or without intensified
Proc Natl Acad Sci U S A 10:1073, 2004. maintenance chemotherapy in patients with acute promyelocytic leukemia who have
926. Tallman MS, Rowe JM: Long-term follow-up and potential for cure in acute promye- become negative for PML-RARalpha transcript after consolidation therapy: The Japan
locytic leukaemia. Best Pract Res Clin Haematol 16:535, 2003. Adult Leukemia Study Group (JALSG) APL97 study. Blood 110:59, 2007.
927. Park JH, Qiao B, Panageas KS, et al: Early death rate in acute promyelocytic leukemia 958. Tsimberidou AM, Kantarjian H, Keating MJ, Estey E: Optimizing treatment for
remains high despite all-trans retinoic acid. Blood 118:1248, 2011. elderly patients with acute promyelocytic leukemia: Is it time to replace chemotherapy
928. Tallman MS, Altman JK: How I treat acute promyelocytic leukemia. Blood 114:5126, with all-trans retinoic acid and arsenic trioxide? Leuk Lymphoma 47:2282, 2006.
2009. 959. Chen GQ, Shi XG, Tang W, et al: Use of arsenic trioxide (As O ) in the treatment of
2
3
929. Tallman MS, Andersen JW, Schiffer CA, et al: All-trans-retinoic acid in acute promy- acute promyelocytic leukemia (APL): 1. As O exerts dose-dependent dual effects on
3
2
elocytic leukemia. N Engl J Med 337:1021, 1997. APL cells. Blood 89:3345, 1997.
930. Chomienne C, Ballerini P, Balitrand N, et al: All-trans retinoic acid in acute promye- 960. Jing Y, Dai J, Chalmers-Redman RME, et al: Arsenic trioxide selectively induces acute
locytic leukemia: II. In vitro studies: Structure–function relationship. Blood 76:1710, promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway.
1990. Blood 94:2102, 1999.
931. Degos L: Is acute promyelocytic leukemia a curable disease? Treatment strategy for a 961. Mathas S, Lietz A, Janz M, et al: Inhibition of NF-kappaB essentially contributes to
long-term survival. Leukemia 8:911, 1994. arsenic-induced apoptosis. Blood 102:1028, 2003.
932. Degos L, Dombret H, Chomienne C, et al: All-trans-retinoic acid as a differentiating 962. Ozpolat B, Akar U, Zorrilla-Calancha I, et al: Death-associated protein 5 (DAP5/p97/
agent in the treatment of acute promyelocytic leukemia. Blood 85:2643, 1995. NAT1) contributes to retinoic acid-induced granulocytic differentiation and arsenic
933. Gallagher RE, Li YP, Rao S, et al: Characterization of acute promyelocytic leukemia cases trioxide-induced apoptosis in acute promyelocytic leukemia. Apoptosis 13:915, 2008.
with PML-RAR alpha break/fusion sites in PML exon 6: Identification of a subgroup 963. Soignet SL, Maslak P, Wang ZG, et al: Complete remission after treatment of acute
with decreased in vitro responsiveness to all-trans retinoic acid. Blood 86:1540, 1995. promyelocytic leukemia with arsenic trioxide. N Engl J Med 339:1341, 1998.
934. Licht JD, Chomienne C, Goy A, et al: Clinical and molecular characterization of a 964. Kwong YL, Au WY, Chim CS, et al: Arsenic trioxide- and idarubicin-induced remis-
rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). sions in relapsed acute promyelocytic leukaemia: Clinicopathological and molecular
Blood 85:1083, 1995. features of a pilot study. Am J Hematol 66:274, 2001.
935. Jansen JH, De Ridder MC, Geertsma WM, et al: Complete remission of t(11;17) pos- 965. Raffoux E, Rousselot P, Poupon J, et al: Combined treatment with arsenic trioxide and
itive acute promyelocytic leukemia induced by all-trans retinoic acid and granulocyte all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin
colony-stimulating factor. Blood 94:39, 1999. Oncol 21:2326, 2003.
936. Tallman MS, Andersen JW, Schiffer CA, et al: All-trans retinoic acid in acute promy- 966. Comacho LH, Soignet SL, Chanel S, et al: Leukocytosis and the retinoic acid syn-
elocytic leukemia: Long-term outcome and prognostic factor analysis from the North drome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J
American Intergroup protocol. Blood 100:4298, 2002. Clin Oncol 18:2620, 2000.

Kaushansky_chapter 88_p1373-1436.indd 1430 9/21/15 11:02 AM